WEBULL
News
ZBIO
38.11
+3.93%
1.44
Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile?
Simply Wall St · 15h ago
Weekly Report: what happened at ZBIO last week (1124-1128)?
Weekly Report · 4d ago
Zenas BioPharma, Inc. (ZBIO) Initiated with a Buy at Evercore ISI
TipRanks · 11/27 08:15
Zenas BioPharma Initiated at Outperform by Evercore ISI Group
Dow Jones · 11/26 13:25
Zenas BioPharma Price Target Announced at $55.00/Share by Evercore ISI Group
Dow Jones · 11/26 13:25
Evercore ISI Group Initiates Coverage On Zenas BioPharma with Outperform Rating, Announces Price Target of $55
Benzinga · 11/26 13:14
Can Zenas BioPharma's (ZBIO) Improving Loss Per Share Shift Investor Confidence in Its Long-Term Story?
Simply Wall St · 11/26 07:23
Weekly Report: what happened at ZBIO last week (1117-1121)?
Weekly Report · 11/24 10:32
Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap
Seeking Alpha · 11/21 16:03
Zenas Biopharma Unveils Pipeline Advances for Autoimmune Disease Therapies
Reuters · 11/21 13:50
Zenas Biopharma Unveils Pipeline Advances in Autoimmune Disease Therapies
Reuters · 11/18 11:03
Weekly Report: what happened at ZBIO last week (1110-1114)?
Weekly Report · 11/17 10:33
How Positive MoonStone Data and New Deals Could Shape Zenas BioPharma’s (ZBIO) Immunology Ambitions
Simply Wall St · 11/16 10:26
Zenas BioPharma Reports Q3 2025 Financial Results
TipRanks · 11/15 04:17
Zenas BioPharma (ZBIO): Evaluating Valuation After Phase 2 MS Results and Major Funding Deal
Simply Wall St · 11/15 01:27
Zenas BioPharma Is Maintained at Overweight by Morgan Stanley
Dow Jones · 11/13 13:21
Morgan Stanley Maintains Overweight on Zenas BioPharma, Raises Price Target to $37
Benzinga · 11/13 13:11
Zenas BioPharma price target raised to $37 from $34 at Morgan Stanley
TipRanks · 11/13 12:36
Zenas BioPharma’s Promising Autoimmune Platform and Buy Rating Reinforced by Advancements in Obexelimab and Orelabrutinib Trials
TipRanks · 11/13 11:36
Zenas BioPharma, Inc.: Promising Outlook with Positive Clinical Results and Strong Financial Position Supporting Buy Rating
TipRanks · 11/13 11:16
More
Webull provides a variety of real-time ZBIO stock news. You can receive the latest news about Zenas BioPharma Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ZBIO
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.